EP1041923A1 - Reduction des artefacts en photoplethysmographie - Google Patents

Reduction des artefacts en photoplethysmographie

Info

Publication number
EP1041923A1
EP1041923A1 EP98960018A EP98960018A EP1041923A1 EP 1041923 A1 EP1041923 A1 EP 1041923A1 EP 98960018 A EP98960018 A EP 98960018A EP 98960018 A EP98960018 A EP 98960018A EP 1041923 A1 EP1041923 A1 EP 1041923A1
Authority
EP
European Patent Office
Prior art keywords
tissue
signal
radiation
signals
artefact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98960018A
Other languages
German (de)
English (en)
Inventor
Peter Richard Smith
Matthew James Hayes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727085.4A external-priority patent/GB9727085D0/en
Application filed by BTG International Ltd filed Critical BTG International Ltd
Publication of EP1041923A1 publication Critical patent/EP1041923A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
    • A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases

Definitions

  • the present invention concerns the reduction of artefact in photoplethysmography, in particular the reduction of movement artefact. It is particularly significant in the context of remote (i.e. non-contact) photoplethysmography and pulse oximetry.
  • Photoplethysmography is a well known technique for monitoring non- invasively variations in the light absorption by a component being monitored (e.g. oxygen in the blood stream).
  • the major application for PPG at the present time is in pulse oximetry, used for non-invasive oxygen saturation measurement.
  • the majority of pulse oximeters utilise PPG signals obtained by light transmission through tissue, rather than by reflection.
  • the measurement of arterial oxygen saturation is made by obtaining and quantitatively comparing at least two PPG signals at different optical wavelengths (usually visible red and infra-red) from which an indication of blood colour (and hence oxygenation) is made.
  • the technique requires the measurement of arterial pulsations, since these are used in a calibration process. Corruption of the PPG signal arises from inadvertent measurement of ambient light (ambient artefact) and from voluntary and involuntary subject movement (movement artefact).
  • Ambient artefact can, in theory, be removed in the recovery of photoplethysmographic signals, provided that the instrumentation correctly subtracts the ambient signal and that appropriate sensor packaging is utilised.
  • Recent clinical publications however suggest that ambient light is a problem in practical systems, mainly due to the severity of artefact experienced in the operating theatre. It is not uncommon practice for clinicians to cover the finger and pulse oximeter with a black bag to eliminate problems caused by particularly strong ambient lighting.
  • Movement artefact is by far the most important problem with current technology. An ability to significantly reduce or even remove the effect of such artefact would be of great importance in patient monitoring, particularly in the case of patients who have been difficult to monitor in the past. Movement artefact is manifested by mechanical forces giving rise to changes in:
  • physiology e.g. exercise or temperature
  • pulse oximetry As long as these changes take place on time scales greater than a few heart cycles, the conventional implementation of pulse oximetry will (in theory) be unaffected, as the method is insensitive to quasi-static changes in the non-pulsatile tissue characteristics.
  • PPG studies in contexts other than oximetry relate to both arterial and venous blood changes, and there is therefore a clear distinction to be drawn between the nature of artefact in the context of pulse oximetry (i.e. all dynamic components which do not originate from the arterial blood pulsations) and that of PPG (i.e. all dynamic components which do not originate from changes in blood volume).
  • Patent Application WO 96/124357 2.
  • Feature-based recognition of corrupt pulses for example, as described in International Patent Application WO 94/22360
  • Both 1 and 3 ideally use an independent measurement of artefact supplied by another transducer (e.g. piezo or optical). Both 1 and 3 assume that artefact is a linear addition to the pulsatile signal.
  • another transducer e.g. piezo or optical.
  • Both 1 and 3 assume that artefact is a linear addition to the pulsatile signal.
  • 2 provides a method of output suppression in the presence of artefact, established by a simple feature recognition analysis. However this approach is not a solution to artefact equalisation.
  • the processing of the PPG signals is carried out following digital conversion. There is no attempt to eliminate the motion signal in any way, by measuring the motion signal, cancelling it by feedback, or mathematical manipulation.
  • the present invention seeks to approach the problem of artefact from a new direction based on observations made by the inventors of the nature of typical artefact and on a physical model for the light/tissue interaction in the presence of artefact.
  • a key element of the model is the optical receiver, which has a non-linear response characteristic. This property of the receiver is important in providing calibration of the signals and leads to a very effective method for artefact equalisation.
  • the method may be implemented by analogue electronics and is suitable for electronic miniaturisation.
  • the optical receiver is modelled, employing the following assumptions:
  • the received light has additive components due to direct coupling with the light source, coupling through non-pulsatile tissue and pulsatile tissue.
  • the light travelling through non-pulsatile tissue and pulsatile tissue is modulated by movement artefact and this artefact is represented by a multiplicative coefficient.
  • the light receiver provides a logarithmic response, either in the light receiving diode itself, or in a subsequent logarithmic amplifier, and two such light signals at different wavelengths are subtracted from one another. This it will be shown provides a large DC signal which is of no interest and can be filtered out and a smaller AC component which represents the light signal component due to pulsatile tissue, but with the motion artefact removed.
  • the AC component signal representing light through pulsatile tissue may then be digitised and subjected to DSP operations in order to derive values representing oxygen saturation.
  • the present invention provides a method of monitoring living tissue comprising the steps of emitting electromagnetic radiation at said tissue at at least first and second different wavelengths, receiving the radiation at the different wavelengths after it has been transmitted through or reflected within said tissue, providing at least first and second signals which are a logarithmic measure of the received first and second radiation wavelengths and subtracting the second signal from the first signal, removing a DC component of the result of the subtraction and providing an AC component to digital sampling means, and processing the digital samples in order to provide a desired value representing a property of the tissue.
  • a third wavelength of electromagnetic radiation is employed and the second wavelength signal is subtracted from a logarithmic form of the signal produced in response to the third wavelength in order to provide a further AC component resulting from this subtraction which is applied to the digital sampling needs, thereby oxygen saturation may be calculated.
  • apparatus for measuring or monitoring living tissue comprising means for irradiating tissue with electromagnetic radiation at at least first and second different wavelengths, means for receiving the radiation at the different wavelengths after it has been transmitted through or reflected within said tissue for providing respective first and second wavelength signals which are a logarithmic measure of the received radiation signals, means for subtracting the second wavelength signal from the first wavelength signal, means for removing a DC component from the output of the subtracting means, digital sampling means for digitising said AC component, and processing means for processing the digital samples in order to derive a value representing a property of said tissue.
  • apparatus for measuring or monitoring living tissue comprising means for irradiating tissue with electromagnetic radiation at at least first and second different wavelengths, means for receiving the radiation at the different wavelengths after it has been transmitted through or reflected within said tissue, logarithmic amplifier means coupled to the receiving means for providing respective first and second wavelength signals which are a logarithmic measure of the received radiation signals, means for subtracting the second wavelength signal from the first wavelength signal, means for removing a DC component from the output of the subtracting means, and processing means for processing the digital samples in order to derive a value representing a property of said tissue.
  • motion artefact can be completely or at least very substantially eliminated prior to any digital processing of the signal in order to derive desired characteristics.
  • a particular advantage of the invention arises in that since it is possible dramatically to remove motion artefact, the invention may be applied in situations where the light emitting means is not directly coupled to the living tissue by means of a clip or other attachment means, as in the prior art.
  • the prior art it was necessary to couple the light source or other radiation emitting means to a subject in order to reduce as far as possible motion artefact.
  • the light source and light receiving means may be mounted in a fixed installation with the patient or living tissue disposed adjacent for receiving radiation but not mechanically coupled to the installation. This introduces an important simplification in that it is not necessary to employ carefully designed clip-type arrangements, and permits use where contact probes fail, such as foetal monitoring, abulatory studies, neonatal monitoring and patient trauma conditions.
  • the present invention provides apparatus for measuring or monitoring living tissue comprising emitting means for emitting electromagnetic radiation, means for receiving said radiation at the different wavelengths after it has been transmitted through or reflected within said tissue, the emitting means and receiving means being fixedly mounted with respect to one another, but there be no means provided for attaching the emitting means or receiving means to living tissue, the receiving means being arranged to provide at least first and second signals representing logarithmic measures of the received wavelength signals, and means for removing motion artefact from said signals and digital sampling means for sampling the motion artefact's removed signals, and means for processing the digital samples.
  • the optical measuring device is a photoplethysmograph.
  • the device may be a pulse oximeter and include means for displaying the oxygen saturation of the patient's blood.
  • use may be made of the derived independence of an equalised pulsatile PPG signal from the tissue characteristics at the wavelength of the second (subtracted) signal.
  • One of three optical wavelengths may be chosen as a control signal, such that there is a high contrast between the tissue characteristics at the signal and control wavelengths.
  • Figure 1 is a schematic block diagram of a known arrangement for reducing motion artefact
  • Figure 2 is a schematic block diagram of the preferred embodiment of the invention.
  • Figure 3 and 4 are waveforms for explaining the application of the present invention.
  • the invention uses a general physical model (a more general model than applied in, say, the disclosure of WO 97/00041), which incorporates a means of ordering the dynamic components of the received signals with respect to both physiological and non-physiological dynamics.
  • the ordering of dynamics implies a system which can derive the arterial oxygen saturation without the need to consider the static portions of the received signals, needing only the pulsatile components.
  • this calculation is also independent of any tissue characteristics, both dynamic and static, at the control wavelength.
  • the oxygen saturation calculation contains only one unknown, which has a physical origin which can be bounded and estimated.
  • PPG photoplethysmographic
  • the photocurrent i pamba is wavelength dependent through the diode responsivity
  • Z is a constant characteristic of the receiver
  • v 0 includes any gain being applied. Both Z and v 0 should only be affected significantly by temperature.
  • the photocurrent is linearly proportional to light intensity / at the receiver, which is modulated by pulsations and artefact as well as source characteristics and spatially dependent tissue characteristics.
  • the received light intensity is modelled by
  • the coupling coefficients depend on all the geometric, temporal and spectral properties of the source/receiver positioning, artefact, tissue dynamics and tissue optical properties.
  • the coefficients a are interpreted as direct coupling between source and receiver and those labelled ⁇ , y correspond to light coupled via non-pulsatile and pulsatile tissue respectively.
  • the active light sources emit fixed power levels but here for the sake of generality they are allowed to vary.
  • Equation (4) distinguishes movement artefact (m(t)) due to changes in probe coupling from artefact arising due to changes in non-pulsatile blood volume (b(t)).
  • the constant of proportionality is free to change between given sources. This assumption is supported by our practical experience. Assumption (5) is justified by criteria similar to those for assumption (4) with the addition of independence between the pulsation dynamics and the movement artefact dynamics.
  • equation (7) can be approximated to first order in the size of the pulsatile signal as
  • Equation (11) indicates that an approach to equalisation based on the use of two light sources of contrasting tissue coupling characteristics will provide the most effective isolation of the pulsatile signal. Since oxy-, deoxy-haemoglobin and melanin are strong absorbers of blue light, significant contrast will be obtained between red (or infra-red) light and blue light. In that case, a linearisation of equation (1 1) yields
  • j labels the red (or infra-red) light and k labels the blue light. It is to be noted that the pulsatile component of the equalised signal is entirely independent of the blue light.
  • the introduction of non-linearity at the front end amplifier has allowed us to develop a method for artefact equalisation but some rescaling of the pulsatile signals has been performed. It is now useful to explore the consequences on the determination of saturated oxygen.
  • the Beer-Lambert formulation is usually used as a basis for the theoretical understanding of pulse oximetry and also benefits from simplicity. We use it here, mainly for the latter reason.
  • the Beer-Lambert law couples path length r and effective absorbance ⁇ eJf together in a single definition of optical density, so that the total signal may be written as
  • Equation (18) differs from the conventional pulse oximetry formulation only by the factor Tn which is a ratio of ratios and should be independent of any geometric coupling condition or individual tissue type.
  • Tn is a ratio of ratios and should be independent of any geometric coupling condition or individual tissue type.
  • the difference in implementation between this formulation and conventional oximetry is that only the pulsatile signal is required for analysis (equation (16)).
  • Figures 1 and 2 show diagrammatic block diagrams of, respectively, a pulse oximeter device of the prior art and a device according to the invention.
  • an optical receiver 2 receives two light signals at different wavelengths (e.g. red visible and infrared).
  • a demultiplexer 4 separates the two signals into two channels 6, 8 and passes them through pre-amplifiers 10. Each signal is passed through a parallel low-pass filter 12 and a high-pass/band-pass filter 14 in order to separate the dc and the ac components.
  • Each component signal is then passed through a separate gain control 16, 17 since the dc and ac components are of very different orders of magnitude, before being multiplexed at 18 and passed into the DSP or microcontroller system 19 in which the comparisons can be made to produce an oxygen saturation measurement (Sa ⁇ 2).
  • Conventional devices may incorporate artefact reduction into the signal processing at this stage.
  • three signals are fed instead into logarithmic amplifiers as shown, and the difference signals between each of the outputs of the logarithmic amplifiers and the control amplifier feed into a gain control. Note that in this design it is only necessary to sample the AC (pulsatile) signal components, since the static components play no part in the oxygen saturation calibration. This not only simplifies the electronics (note that only two channels are multiplexed to the microprocessor) but also reduces the complexity of the control algorithm.
  • a light source 20 is fixedly mounted with an optical receiver 22 in a suitable mechanical installation, indicated as at 24.
  • Living tissue schematic shown as at 26 is disposed between the light source and optical receiver 22, but is not mechanically affixed thereto.
  • the light source emits three different wavelengths, normally red, infrared and a control source (e.g. blue) and the optical receiver has three separate light responsive diodes each responsive to their respective wavelength.
  • the response of each diode is strictly linear in that a voltage or current output signal is provided which is linearly related to the intensity of radiation thereon.
  • the output signals from the diodes are output on a single channel to a demultiplexer 28 which separates the three wavelength signals into respective channels 30, 32, 34.
  • Each channel has a preamplifier 36 followed by a logarithmic amplifier 38 in order to give a logarithmic version of the signal.
  • the signal in channel 32 representing the blue signal is used as a control channel and is subtracted from the infrared signal in channel 30 in a subtractor 40, and is subtracted from the red signal in 34 and subtractor 42.
  • the outputs of the two subtractors are signals which represent equations (11) and (12), referred to previously.
  • the outputs of the subtractors 40, 42 are applied to respective gain control units 44, 46, which gain controls units inherently remove dc components in the signal, i.e. the dc component represented in equation (12).
  • a high pass filter may be employed, with a cut off frequency of about 0.5 Hertz in order to remove the dc component.
  • the outputs of the gain control unit are applied to a multiplexor 48, the output of the multiplexer being fed to an analogue to digital converter 50 which provides digital samples of the ac components which will be digital samples of the light passing through pulsatile tissue with motion artefact removed as in equation (12), to a digital system 52 for carrying out a required manipulations as set out above.
  • Artefact reduction may be incorporated into the DSP system, but the simple front-end analogue electronic arrangement automatically provides a signal representative of the difference between the logarithms of the received signals, and therefore allows for compensation of the multiplicative element of the artefact.
  • the logarithmic amplifiers handle the extremely wide dynamic range of the received signals without saturating.
  • Artefact minimisation can be shown with the use of the simultaneous removal of ambient artefact and probe coupling motion artefact.
  • Figures 3 illustrates a trace obtained without employing the artefact reduction of the present invention, and including a period of severe artefact.
  • Figure 4 shows the same situation, but employing the artefact reduction of the invention: the artefact has been completely removed.
  • probe coupling artefact provides a good solution to the problem of probe coupling artefact, it allows the consideration of remote PPG and therefore remote pulse oximetry. Since a significant fraction of other artefact is actually induced by mechanical forces being coupled to the subject via the physical contact of the probe (secondary artefact) these will all be removed in a remote system. Furthermore the solution to probe coupling artefact will also reduce (but not remove) primary artefact caused by venous blood motions and any residual ambient artefact.
  • a further attractive property of this method is that the requisite technology is simple. It may be implemented by purely analogue electronics if necessary, and it is a strong candidate for miniaturisation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

L'invention concerne un procédé de contrôle pour les tissus vivants, permettant d'éliminer les artefacts de mouvement avant le traitement numérique, qui comprend les étapes suivantes : émission de rayonnements électromagnétiques au niveau des tissus en question sur des première et seconde longueurs d'onde, réception des rayonnements, aux différentes longueurs d'onde, émis à travers les tissus ou réfléchis dans ces tissus, établissement au moins de premier et second signaux qui représentent une mesure logarithmique des première et seconde longueurs d'onde du rayonnement reçu et soustraction du second signal par rapport au premier, élimination d'une composante en courant continu dans le résultat de la soustraction puis fourniture d'une composante en courant alternatif à l'échantillonneur numérique, et traitement des échantillons numériques visant à obtenir une valeur désirée qui représente une propriété des tissus considérés.
EP98960018A 1997-12-22 1998-12-15 Reduction des artefacts en photoplethysmographie Withdrawn EP1041923A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9727085 1997-12-22
GBGB9727085.4A GB9727085D0 (en) 1997-12-22 1997-12-22 Artefact production in photoplethysmography
GB9812540 1998-06-10
GBGB9812540.4A GB9812540D0 (en) 1997-12-22 1998-06-10 Artefact reduction in photoplethysmography
PCT/GB1998/003757 WO1999032030A1 (fr) 1997-12-22 1998-12-15 Reduction des artefacts en photoplethysmographie

Publications (1)

Publication Number Publication Date
EP1041923A1 true EP1041923A1 (fr) 2000-10-11

Family

ID=26312826

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98960018A Withdrawn EP1041923A1 (fr) 1997-12-22 1998-12-15 Reduction des artefacts en photoplethysmographie

Country Status (3)

Country Link
EP (1) EP1041923A1 (fr)
JP (1) JP2001526073A (fr)
WO (1) WO1999032030A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616613B1 (en) 2000-04-27 2003-09-09 Vitalsines International, Inc. Physiological signal monitoring system
FR2840794B1 (fr) 2002-06-18 2005-04-15 Suisse Electronique Microtech Equipement portable destine a la mesure et/ou la surveillance de la frequence cardiaque
US7190985B2 (en) 2004-02-25 2007-03-13 Nellcor Puritan Bennett Inc. Oximeter ambient light cancellation
US7392075B2 (en) 2005-03-03 2008-06-24 Nellcor Puritan Bennett Incorporated Method for enhancing pulse oximetry calculations in the presence of correlated artifacts
US7904130B2 (en) 2005-09-29 2011-03-08 Nellcor Puritan Bennett Llc Medical sensor and technique for using the same
US7869850B2 (en) 2005-09-29 2011-01-11 Nellcor Puritan Bennett Llc Medical sensor for reducing motion artifacts and technique for using the same
WO2007097702A1 (fr) * 2006-02-21 2007-08-30 Lindberg Lars-Goeran surveillance non invasive d'écoulement sanguin dans les tissus profonds
US8219170B2 (en) 2006-09-20 2012-07-10 Nellcor Puritan Bennett Llc System and method for practicing spectrophotometry using light emitting nanostructure devices
US7574245B2 (en) 2006-09-27 2009-08-11 Nellcor Puritan Bennett Llc Flexible medical sensor enclosure
US7684842B2 (en) 2006-09-29 2010-03-23 Nellcor Puritan Bennett Llc System and method for preventing sensor misuse
US8280469B2 (en) 2007-03-09 2012-10-02 Nellcor Puritan Bennett Llc Method for detection of aberrant tissue spectra
US8265724B2 (en) 2007-03-09 2012-09-11 Nellcor Puritan Bennett Llc Cancellation of light shunting
GB0705033D0 (en) 2007-03-15 2007-04-25 Imp Innovations Ltd Heart rate measurement
WO2008154643A1 (fr) 2007-06-12 2008-12-18 Triage Wireless, Inc. Moniteur de signaux vitaux pour mesure de tension artérielle en utilisant des formes d'onde optique, électrique et de tension
US11607152B2 (en) 2007-06-12 2023-03-21 Sotera Wireless, Inc. Optical sensors for use in vital sign monitoring
US8602997B2 (en) 2007-06-12 2013-12-10 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US11330988B2 (en) 2007-06-12 2022-05-17 Sotera Wireless, Inc. Body-worn system for measuring continuous non-invasive blood pressure (cNIBP)
US8750953B2 (en) 2008-02-19 2014-06-10 Covidien Lp Methods and systems for alerting practitioners to physiological conditions
USD626562S1 (en) 2008-06-30 2010-11-02 Nellcor Puritan Bennett Llc Triangular saturation pattern detection indicator for a patient monitor display panel
US9895068B2 (en) 2008-06-30 2018-02-20 Covidien Lp Pulse oximeter with wait-time indication
US8968193B2 (en) 2008-09-30 2015-03-03 Covidien Lp System and method for enabling a research mode on physiological monitors
US11896350B2 (en) 2009-05-20 2024-02-13 Sotera Wireless, Inc. Cable system for generating signals for detecting motion and measuring vital signs
US8475370B2 (en) 2009-05-20 2013-07-02 Sotera Wireless, Inc. Method for measuring patient motion, activity level, and posture along with PTT-based blood pressure
US9492092B2 (en) 2009-05-20 2016-11-15 Sotera Wireless, Inc. Method for continuously monitoring a patient using a body-worn device and associated system for alarms/alerts
US10085657B2 (en) 2009-06-17 2018-10-02 Sotera Wireless, Inc. Body-worn pulse oximeter
US8494786B2 (en) 2009-07-30 2013-07-23 Covidien Lp Exponential sampling of red and infrared signals
JP5715132B2 (ja) 2009-08-20 2015-05-07 コーニンクレッカ フィリップス エヌ ヴェ 画像解析に関する方法及びシステム
US8622922B2 (en) 2009-09-14 2014-01-07 Sotera Wireless, Inc. Body-worn monitor for measuring respiration rate
US11253169B2 (en) 2009-09-14 2022-02-22 Sotera Wireless, Inc. Body-worn monitor for measuring respiration rate
US8527038B2 (en) 2009-09-15 2013-09-03 Sotera Wireless, Inc. Body-worn vital sign monitor
US10420476B2 (en) 2009-09-15 2019-09-24 Sotera Wireless, Inc. Body-worn vital sign monitor
US20110066044A1 (en) 2009-09-15 2011-03-17 Jim Moon Body-worn vital sign monitor
US10806351B2 (en) 2009-09-15 2020-10-20 Sotera Wireless, Inc. Body-worn vital sign monitor
US8364250B2 (en) 2009-09-15 2013-01-29 Sotera Wireless, Inc. Body-worn vital sign monitor
US10271746B2 (en) * 2009-10-06 2019-04-30 Koninklijke Philips N.V. Method and system for carrying out photoplethysmography
US20110224499A1 (en) 2010-03-10 2011-09-15 Sotera Wireless, Inc. Body-worn vital sign monitor
US8979765B2 (en) 2010-04-19 2015-03-17 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US9173594B2 (en) 2010-04-19 2015-11-03 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US8747330B2 (en) 2010-04-19 2014-06-10 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US8888700B2 (en) 2010-04-19 2014-11-18 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US9339209B2 (en) 2010-04-19 2016-05-17 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US9173593B2 (en) 2010-04-19 2015-11-03 Sotera Wireless, Inc. Body-worn monitor for measuring respiratory rate
US8930145B2 (en) 2010-07-28 2015-01-06 Covidien Lp Light focusing continuous wave photoacoustic spectroscopy and its applications to patient monitoring
US8521246B2 (en) 2010-07-29 2013-08-27 Covidien Lp Cable cross talk suppression
US10856752B2 (en) 2010-12-28 2020-12-08 Sotera Wireless, Inc. Body-worn system for continuous, noninvasive measurement of cardiac output, stroke volume, cardiac power, and blood pressure
US9713428B2 (en) 2011-01-21 2017-07-25 Worcester Polytechnic Institute Physiological parameter monitoring with a mobile communication device
WO2012112885A1 (fr) 2011-02-18 2012-08-23 Sotera Wireless, Inc. Capteur optique pour la mesure de propriétés physiologiques
EP2675348B1 (fr) 2011-02-18 2019-11-06 Sotera Wireless, Inc. Processeur porté au poignet modulaire pour la surveillance de patient
WO2013038326A1 (fr) * 2011-09-13 2013-03-21 Koninklijke Philips Electronics N.V. Détection d'un signal à distorsion réduite
WO2013054477A1 (fr) 2011-10-11 2013-04-18 株式会社村田製作所 Instrument portable
US9833146B2 (en) 2012-04-17 2017-12-05 Covidien Lp Surgical system and method of use of the same
ITRM20130384A1 (it) * 2013-06-28 2014-12-29 Diagnostic Engineering Solutions S R L Dispositivo indossabile per la misurazione del flusso sanguigno, e relativo sistema.
EP3145399A1 (fr) 2014-05-22 2017-03-29 Koninklijke Philips N.V. Procédé et appareil pour la détection optique de modification d'un tissu à une précision accrue
CN106413530B (zh) 2014-05-28 2020-11-06 皇家飞利浦有限公司 使用多通道ppg信号的运动伪影降低
US11246495B2 (en) 2014-10-27 2022-02-15 Vital Sines International Inc. System and method for monitoring aortic pulse wave velocity and blood pressure
US10966642B2 (en) 2015-06-03 2021-04-06 Koninklijke Philips N.V. Photoplethysmography apparatus
WO2017021405A1 (fr) * 2015-08-03 2017-02-09 Koninklijke Philips N.V. Capteur optique de signes vitaux
US11311242B2 (en) * 2016-05-20 2022-04-26 Sony Corporation Biological information processing apparatus, biological information processing method, and information processing apparatus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325039A (en) * 1970-10-07 1973-08-01 Shaw R F Oximeter and method for in vivo determination of oxygen saturatiion in blood
US4714341A (en) 1984-02-23 1987-12-22 Minolta Camera Kabushiki Kaisha Multi-wavelength oximeter having a means for disregarding a poor signal
US5632272A (en) 1991-03-07 1997-05-27 Masimo Corporation Signal processing apparatus
GB9216431D0 (en) 1992-08-01 1992-09-16 Univ Swansea Optical monitoring or measuring artefact suppression
US5368026A (en) 1993-03-26 1994-11-29 Nellcor Incorporated Oximeter with motion detection for alarm modification
US5645060A (en) 1995-06-14 1997-07-08 Nellcor Puritan Bennett Incorporated Method and apparatus for removing artifact and noise from pulse oximetry

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9932030A1 *

Also Published As

Publication number Publication date
JP2001526073A (ja) 2001-12-18
WO1999032030A1 (fr) 1999-07-01

Similar Documents

Publication Publication Date Title
WO1999032030A1 (fr) Reduction des artefacts en photoplethysmographie
US9341565B2 (en) Multiple-wavelength physiological monitor
US7239905B2 (en) Active pulse blood constituent monitoring
US8195263B2 (en) Pulse oximetry motion artifact rejection using near infrared absorption by water
EP0951232B1 (fr) Capteur compatible avec le mouvement, pour l'analyse sanguine, optique et non invasive
US5692505A (en) Data processing systems and methods for pulse oximeters
US6931268B1 (en) Active pulse blood constituent monitoring
US7343186B2 (en) Multi-wavelength physiological monitor
Hayes et al. Quantitative evaluation of photoplethysmographic artifact reduction for pulse oximetry
EP0341059A2 (fr) Mesure de pouls et de teneur en oxygène
Patterson et al. Ratiometric artifact reduction in low power reflective photoplethysmography
WO1997000041A1 (fr) Procede permettant d'eliminer un artefact du au mouvement et le bruit dans une oxymetrie du pouls et appareil correspondant
US20120245441A1 (en) Signal demodulation
EP3277172B1 (fr) Système et procédé d'analyse optique
JP2009261458A (ja) 信号処理方法及びそれを用いたパルスフォトメータ
Allen et al. Photoplethysmography assessments in cardiovascular disease
JP3359756B2 (ja) 生体光計測装置
KR20010033511A (ko) 포토플에티스모그래피에서의 인공물의 축소
Jayasree et al. Design and development of a simple hardware setup for sensing blood volume pulse and a PIC microcontroller based heart rate meter
Cheang Feasibility of non-contact photoplethysmography
Crabtree et al. Audio assessment of the peripheral microcirculation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000628

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT NL

17Q First examination report despatched

Effective date: 20010717

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011128